1. Home
  2. TENX vs SST Comparison

TENX vs SST Comparison

Compare TENX & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TENX
  • SST
  • Stock Information
  • Founded
  • TENX 1967
  • SST 2013
  • Country
  • TENX United States
  • SST United States
  • Employees
  • TENX N/A
  • SST N/A
  • Industry
  • TENX Biotechnology: Pharmaceutical Preparations
  • SST Diversified Commercial Services
  • Sector
  • TENX Health Care
  • SST Consumer Discretionary
  • Exchange
  • TENX Nasdaq
  • SST Nasdaq
  • Market Cap
  • TENX 25.8M
  • SST 23.3M
  • IPO Year
  • TENX N/A
  • SST N/A
  • Fundamental
  • Price
  • TENX $5.91
  • SST $5.44
  • Analyst Decision
  • TENX Strong Buy
  • SST Strong Buy
  • Analyst Count
  • TENX 3
  • SST 1
  • Target Price
  • TENX $16.00
  • SST $10.00
  • AVG Volume (30 Days)
  • TENX 23.2K
  • SST 59.2K
  • Earning Date
  • TENX 08-19-2025
  • SST 08-07-2025
  • Dividend Yield
  • TENX N/A
  • SST N/A
  • EPS Growth
  • TENX N/A
  • SST N/A
  • EPS
  • TENX N/A
  • SST N/A
  • Revenue
  • TENX N/A
  • SST $317,055,000.00
  • Revenue This Year
  • TENX N/A
  • SST N/A
  • Revenue Next Year
  • TENX N/A
  • SST $8.39
  • P/E Ratio
  • TENX N/A
  • SST N/A
  • Revenue Growth
  • TENX N/A
  • SST N/A
  • 52 Week Low
  • TENX $3.25
  • SST $2.90
  • 52 Week High
  • TENX $7.89
  • SST $15.30
  • Technical
  • Relative Strength Index (RSI)
  • TENX 43.41
  • SST 42.98
  • Support Level
  • TENX $5.80
  • SST $5.21
  • Resistance Level
  • TENX $6.25
  • SST $6.31
  • Average True Range (ATR)
  • TENX 0.26
  • SST 0.74
  • MACD
  • TENX -0.02
  • SST -0.20
  • Stochastic Oscillator
  • TENX 26.90
  • SST 17.44

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

Share on Social Networks: